Homepage > Company > Media > Pharma News > 2020 > Gilead starts two late-stage studies to test drug for coronavirus

Gilead starts two late-stage studies to test drug for coronavirus

(Reuters) - Gilead Sciences Inc (GILD.O) said on Wednesday it has started two late-stage studies to test its drug in patients with severe and moderate cases of the illness caused by the coronavirus, sending its shares up 4% in extended trading.

Beginning March, the studies will test the experimental antiviral drug, remdesivir, among nearly 1,000 patients at medical centers across Asian countries, as well as in other nations with high numbers of diagnosed cases, the company said.

Two dosing durations of remdesivir will be administered intravenously in the late-stage studies following the U.S. Food and Drug Administration’s rapid acceptance of remdesivir as a new investigational drug.

FEBRUARY 27, 2020

https://www.reuters.com/

Read also

FDA Offers Advice on NDAs for Postoperative Local Anesthetics

Sponsors developing long-acting local postoperative anesthetics should consider including novel, clinically meaningful endpoints in their trial design, the FDA has said in new draft guidance. ...

Sarepta slides as FDA about-turn on panel clouds gene therapy approval path

Shares of Sarepta Therapeutics Inc slumped as much as 21% on Friday on uncertainty over its gene therapy for Duchenne muscular dystrophy after the U.S. health regulator reversed its decision on a p...

Amgen to cut 450 jobs in second round of layoffs this year

(Reuters) - Amgen Inc said on Thursday it would cut 450 jobs, or less than 2% of its workforce, making it the company's second round of layoffs this year amid intensifying pressure on drug prices ...

Positive phase 2 data from Atrial Fibrillation clinical trial – primary endpoint met

Acesion Pharma, the biotech pioneering first-in-class novel therapies for Atrial Fibrillation (AF), the most common cardiac arrhythmia, today announced positive data from its Phase 2 trial of AP306...